Skip to content
AnalystLens

Omega Healthcare Investors Annual Report, Year Ended Dec 31, 2017

Filing Date
Filed February 23, 2018
Period End
December 31, 2017
Security
OHI
In the record · 2016–202610-K1210-Q348-K126

OHI filed 12 annual reports (10-K), 34 quarterly reports (10-Q) and 126 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Apr ’17Apr ’17
  2. Material agreement8-K · Oct ’20Oct ’20
  3. Leadership change8-K · Jan ’23Jan ’23
  4. Leadership change8-K · Oct ’26Oct ’26

Summary

Summary of the 10-K filed February 23, 2018. Cited figures are marked; the original filing is the authoritative source.

Omega Healthcare Investors, Inc. ("Omega") reported total operating revenues of $908.4 milliona for 2017, up from $900.8 million in 2016, while net income fell to $104.9 million from $383.4 million.

The decline was driven largely by $198.2 millionb of impairment losses on direct financing leases, primarily tied to Orianna Health Systems, and $99.1 million of impairments on real estate properties. Orianna has not paid rent since July 2017, and the company recorded a $172.2 million allowance on its Orianna direct financing leases. Three operators were approximately 90 days or more past due on rent at year-end, and the company is pursuing a restructuring with Signature Healthcare.

The portfolio at December 31, 2017 comprised 983 healthcare facilities in 41 states and the U.K., operated by 74 third-party operators, with real estate investments of approximately $8.8 billionc. The company funded about $559 million of new investments in 2017, sold 52 facilities for approximately $257.8 million in net proceeds, and issued $550 million of 4.75% senior notes due 2028 plus an additional $150 million of 4.50% notes due 2025. Total debt was $4.6 billion, representing approximately 54.0% of total capitalization.

Common dividends declared totaled $2.54d per share for 2017, up from $2.36 in 2016, and NAREIT FFO fell to $444.3 million from $660.1 million. The filing also discloses two securities class action complaints filed in November 2017 in the Southern District of New York, which the company says it intends to vigorously defend. Management states that the Tax Cuts and Jobs Act had an immaterial impact on the financial statements.

Key Highlights

  1. Net income declined to $104.9 million in 2017 from $383.4 million in 2016, while total operating revenues rose to $908.4 million from $900.8 million.
  2. Impairment losses on direct financing leases were $198.2 million in 2017, primarily related to Orianna, which has not paid rent since July 2017; the company recorded a $172.2 million allowance on those leases.
  3. NAREIT FFO was $444.3 million in 2017 compared with $660.1 million in 2016.
  4. The company completed approximately $559 million of new investments in 2017 and sold 52 facilities for approximately $257.8 million in net proceeds.
  5. Total debt was $4.6 billion, approximately 54.0% of total capitalization, with the company issuing $550 million of 4.75% senior notes due 2028 and $150 million of additional 4.50% notes due 2025 in April 2017.
  6. Dividends declared per common share increased to $2.54 in 2017 from $2.36 in 2016, and the Board declared $0.66 per share for the February 2018 payment.
  7. Two purported securities class action complaints were filed in November 2017 alleging violations of Section 10(b) of the Exchange Act; the company denies the allegations.

Financial Statements

FY2017 against FY2016

Line itemFY2017FY2016Change
Revenue$908.38M$900.83M+0.8%
Operating Expenses$647.12M$391.08M+65.5%
Operating Income$315.17M$559.95M−43.7%
Interest Expense$188.76M$164.10M+15.0%
Net Income$100.42M$366.42M−72.6%
EPS (Basic)$0.51$1.91−73.3%
EPS (Diluted)$0.51$1.90−73.2%
Shares Outstanding (Basic)197.74M191.78M+3.1%
Shares Outstanding (Diluted)206.79M201.63M+2.6%

Frequently Asked Questions

  1. Why did net income fall so sharply in 2017?

    Net income was $104.9 million versus $383.4 million in 2016. The filing attributes the decline mainly to $198.2 million of impairment losses on direct financing leases, primarily tied to Orianna, and $99.1 million of impairments on real estate properties, as well as higher interest expense and $21.97 million of refinancing costs. Gains on assets sold were $53.9 million.

  2. What is the status of Orianna Health Systems?

    Orianna has not satisfied contractual payments due under its remaining two direct financing leases or its separate operating lease, and the company has not recognized direct financing lease income from Orianna since July 1, 2017. The company is in continuing discussions with Orianna, which may include facility sales or transitions to other operators. The company recorded a $172.2 million allowance on its Orianna direct financing leases.

  3. How is the company funding its growth and debt obligations?

    The company relies on cash from operations, its 2017 Omega Credit Facilities (a $1.25 billion revolver, a $425 million U.S. term loan and a £100 million sterling term loan), and senior notes. Management believes liquidity is adequate to fund operations, debt service and investments over the next twelve months. Operating cash flow was $577.9 million in 2017.

  4. What operator credit issues does the filing disclose?

    At December 31, 2017, three operators were approximately 90 days or more past due on rent. Orianna is one, and Signature Healthcare is another, which the company says is working toward a consensual restructuring outside court. Daybreak Venture was placed on a cash basis in the third quarter of 2017 and entered a Settlement and Forbearance Agreement, with monthly rent returning to the full contractual amount in January 2018.

  5. What is the risk from the pending securities litigation?

    Two purported class action complaints filed in November 2017 in the U.S. District Court for the Southern District of New York allege misleading statements about operator financial results, rent payment ability and impairments. The complaints seek unspecified monetary damages. The company says it is in the very early stages of the litigation and cannot predict the outcome or estimate potential costs.